Cidara Therapeutics Inc. (NASDAQ:CDTX) saw a 721.76% increase in 2025, driven by a $9.2 billion merger with Merck. The deal, announced in November, offered a 108% premium over CDTX’s closing price. The acquisition followed CDTX receiving FDA fast track designation for CD388, a drug candidate to prevent influenza in high-risk individuals.

The merger with Merck is expected to enhance respiratory portfolio and pipeline, addressing the global threat of influenza. CD388 is a late-phase candidate with strain-agnostic properties, targeting prevention in high-risk individuals. The acquisition is set to be completed in the first quarter of 2026, pending regulatory and shareholder approvals.

Read more at Yahoo Finance: Cidara Therapeutics (CDTX) Rockets 722% in 2025 on Merck $9.2-Billion Merger